AMGN vs. EXAS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and EXAS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | AMGN | EXAS |
|---|---|---|
| Company Name | Amgen Inc. | Exact Sciences Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 159.60 billion USD | 8.90 billion USD |
| Exchange | NasdaqGS | NasdaqCM |
| Listing Date | June 17, 1983 | February 1, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of AMGN and EXAS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| 5-Day Price Return | 2.12% | 4.47% |
| 13-Week Price Return | 7.47% | -17.46% |
| 26-Week Price Return | -0.18% | -7.10% |
| 52-Week Price Return | -9.61% | -20.30% |
| Month-to-Date Return | 0.46% | 0.11% |
| Year-to-Date Return | 13.74% | -16.36% |
| 10-Day Avg. Volume | 1.97M | 5.48M |
| 3-Month Avg. Volume | 2.55M | 3.11M |
| 3-Month Volatility | 26.01% | 38.66% |
| Beta | 0.49 | 1.22 |
Profitability
Return on Equity (TTM)
AMGN
97.92%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
AMGN’s Return on Equity of 97.92% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
EXAS
-38.37%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
EXAS has a negative Return on Equity of -38.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
AMGN
18.96%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 18.96% places AMGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
EXAS
-34.19%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
EXAS has a negative Net Profit Margin of -34.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
AMGN
24.01%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 24.01% places AMGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
EXAS
-34.49%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
EXAS has a negative Operating Profit Margin of -34.49%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Return on Equity (TTM) | 97.92% | -38.37% |
| Return on Assets (TTM) | 7.35% | -16.63% |
| Net Profit Margin (TTM) | 18.96% | -34.19% |
| Operating Profit Margin (TTM) | 24.01% | -34.49% |
| Gross Profit Margin (TTM) | 69.71% | 68.19% |
Financial Strength
Current Ratio (MRQ)
AMGN
1.31
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
AMGN’s Current Ratio of 1.31 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
EXAS
2.89
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
EXAS’s Current Ratio of 2.89 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
AMGN
7.57
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 7.57, AMGN operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
EXAS
0.95
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
AMGN
2.40
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
AMGN’s Interest Coverage Ratio of 2.40 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Current Ratio (MRQ) | 1.31 | 2.89 |
| Quick Ratio (MRQ) | 0.98 | 2.32 |
| Debt-to-Equity Ratio (MRQ) | 7.57 | 0.95 |
| Interest Coverage Ratio (TTM) | 2.40 | -15.18 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AMGN
3.06%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.06% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AMGN
82.64%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 82.64%, AMGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Dividend Yield (TTM) | 3.06% | 0.00% |
| Dividend Payout Ratio (TTM) | 82.64% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AMGN
24.22
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
AMGN’s P/E Ratio of 24.22 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
EXAS
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for EXAS is currently unavailable.
Price-to-Sales Ratio (TTM)
AMGN
4.59
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
AMGN’s P/S Ratio of 4.59 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
EXAS
2.92
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 2.92 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
AMGN
20.21
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
AMGN’s P/B Ratio of 20.21 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
EXAS
4.06
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
EXAS’s P/B Ratio of 4.06 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | AMGN | EXAS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 24.22 | -- |
| Price-to-Sales Ratio (TTM) | 4.59 | 2.92 |
| Price-to-Book Ratio (MRQ) | 20.21 | 4.06 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.61 | 68.70 |